Intrahepatic CD69
T-lymphocytes
immunity, cellular
immunologic surveillance
liver neoplasms
lymphocytes, tumor-infiltrating
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
accepted:
01
07
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
26
7
2022
Statut:
ppublish
Résumé
More than 50% of all patients with colorectal cancer (CRC) develop liver metastases (CLM), a clinical condition characterized by poor prognosis and lack of reliable prognostic markers. Vδ1 cells are a subset of tissue-resident gamma delta (γδ) T lymphocytes endowed with a broad array of antitumor functions and showing a natural high tropism for the liver. However, little is known about their impact in the clinical outcomes of CLM. We isolated human γδ T cells from peripheral blood (PB) and peritumoral (PT) tissue of 93 patients undergone surgical procedures to remove CLM. The phenotype of freshly purified γδ T cells was assessed by multiparametric flow cytometry, the transcriptional profiles by single cell RNA-sequencing, the functional annotations by Gene Ontology enrichment analyses and the clonotype by γδ T cell receptor (TCR)-sequencing. The microenvironment of CLM is characterized by a heterogeneous immune infiltrate comprising different subsets of γδ tumor-infiltrating lymphocytes (TILs) able to egress the liver and re-circulate in PB. Vδ1 T cells represent the largest population of γδ TILs within the PT compartment of CLM that is greatly enriched in Vδ1 T effector (T The enrichment of tissue-resident CD69
Sections du résumé
BACKGROUND
More than 50% of all patients with colorectal cancer (CRC) develop liver metastases (CLM), a clinical condition characterized by poor prognosis and lack of reliable prognostic markers. Vδ1 cells are a subset of tissue-resident gamma delta (γδ) T lymphocytes endowed with a broad array of antitumor functions and showing a natural high tropism for the liver. However, little is known about their impact in the clinical outcomes of CLM.
METHODS
We isolated human γδ T cells from peripheral blood (PB) and peritumoral (PT) tissue of 93 patients undergone surgical procedures to remove CLM. The phenotype of freshly purified γδ T cells was assessed by multiparametric flow cytometry, the transcriptional profiles by single cell RNA-sequencing, the functional annotations by Gene Ontology enrichment analyses and the clonotype by γδ T cell receptor (TCR)-sequencing.
RESULTS
The microenvironment of CLM is characterized by a heterogeneous immune infiltrate comprising different subsets of γδ tumor-infiltrating lymphocytes (TILs) able to egress the liver and re-circulate in PB. Vδ1 T cells represent the largest population of γδ TILs within the PT compartment of CLM that is greatly enriched in Vδ1 T effector (T
CONCLUSIONS
The enrichment of tissue-resident CD69
Identifiants
pubmed: 35863820
pii: jitc-2022-004579
doi: 10.1136/jitc-2022-004579
pmc: PMC9310256
pii:
doi:
Substances chimiques
Receptors, Antigen, T-Cell, gamma-delta
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Nat Rev Immunol. 2021 Apr;21(4):221-232
pubmed: 33057185
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31689241
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Nat Immunol. 2017 Apr;18(4):393-401
pubmed: 28218745
Nat Immunol. 2019 Sep;20(9):1220-1230
pubmed: 31285626
Nat Immunol. 2019 Feb;20(2):121-128
pubmed: 30664765
Elife. 2017 Jan 18;6:
pubmed: 28099114
Cell Rep. 2021 Oct 19;37(3):109871
pubmed: 34686325
Nat Med. 2020 Feb;26(2):193-199
pubmed: 32042196
Sci Immunol. 2019 Jul 5;4(37):
pubmed: 31278120
Nat Commun. 2021 Mar 15;12(1):1669
pubmed: 33723257
Clin Immunol. 2004 Oct;113(1):56-63
pubmed: 15380530
BMC Bioinformatics. 2015 May 28;16:175
pubmed: 26017500
Blood. 2011 Jul 28;118(4):992-1001
pubmed: 21633088
Br J Haematol. 1997 Feb;96(2):266-71
pubmed: 9029011
Nat Commun. 2017 Jan 09;7:13839
pubmed: 28067223
J Immunother Cancer. 2019 Sep 12;7(1):249
pubmed: 31511069
Eur J Immunol. 2017 Jun;47(6):946-953
pubmed: 28475283
Blood. 2011 Jul 7;118(1):129-38
pubmed: 21505189
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Nat Commun. 2021 Mar 3;12(1):1402
pubmed: 33658501
Nat Rev Immunol. 2015 Nov;15(11):683-91
pubmed: 26449179
Front Immunol. 2014 Aug 26;5:400
pubmed: 25206355
J Immunol. 2013 Jul 1;191(1):30-4
pubmed: 23740951
Clin Cancer Res. 2016 Dec 1;22(23):5795-5804
pubmed: 27307596
Eur J Immunol. 2005 Jun;35(6):1764-72
pubmed: 15915537
J Clin Invest. 2019 May 30;129(9):3562-3577
pubmed: 31145102
EBioMedicine. 2019 May;43:30
pubmed: 31072771
J Oncol. 2016;2016:2196703
pubmed: 27429617
Nat Rev Drug Discov. 2020 Mar;19(3):169-184
pubmed: 31492944
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11906-11915
pubmed: 31118283
Ann Surg. 2018 Jan;267(1):132-141
pubmed: 27763897
Front Oncol. 2022 Jan 07;11:689509
pubmed: 35070948
World J Hepatol. 2019 Feb 27;11(2):150-172
pubmed: 30820266
J Exp Med. 2003 Aug 4;198(3):391-7
pubmed: 12900516
Cell Rep. 2014 Nov 6;9(3):1075-88
pubmed: 25437561
Trends Immunol. 2017 Feb;38(2):94-103
pubmed: 27939451
Nat Rev Immunol. 2013 Feb;13(2):88-100
pubmed: 23348415
J Hepatol. 2018 Sep;69(3):654-665
pubmed: 29758330
Immunity. 2016 Dec 20;45(6):1270-1284
pubmed: 27939671
J Immunother Cancer. 2019 Dec 11;7(1):347
pubmed: 31829255
Sci Immunol. 2019 Apr 5;4(34):
pubmed: 30952804
Sci Immunol. 2021 Apr 23;6(58):
pubmed: 33893173
Nat Cancer. 2020 Mar;1(3):302-314
pubmed: 32803171
Nat Rev Immunol. 2010 Jul;10(7):467-78
pubmed: 20539306
Immunity. 2018 Mar 20;48(3):453-473
pubmed: 29562195
Cancer Immunol Immunother. 2013 Jul;62(7):1199-210
pubmed: 23619975
Clin Transl Immunology. 2019 Oct 10;8(10):e01080
pubmed: 31624593
Hepatology. 2001 May;33(5):1312-20
pubmed: 11343261
Oncotarget. 2017 Jan 31;8(5):8900-8909
pubmed: 27823972
J Transl Med. 2018 Jan 10;16(1):3
pubmed: 29316940